Collectively, these data indicated that the loss of NME1, but not of NME2, accelerated the invasive switch of breast tumors in the intraductal xenograft assay, possibly in relation with increased plasma membrane MT1-MMP levels. The gene discussed is NME2; the disease is breast neoplasm.